The meta-analysis identified a significant association between treatment with semaglutide and risk for NAION (OR, 3.92; 95% ...

GLP-1 receptor agonists are not associated with increased risks for dry age-related macular degeneration or cataract ...

Researchers found that older adults with diabetes who used semaglutide had more than twice the risk of developing a serious ...

Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 diabetes. The risk was more modest than previously reported. Using the specific ...

New research has discovered certain weight-loss medications could be associated with an increased risk of serious eye conditions, and even vision loss. Two studies, published in JAMA, analyzed how ...

Novo Nordisk, Eli Lilly call their diabetes and weight loss drugs “safe and effective” as they face accusations in lawsuits ...

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

Schizophrenia spectrum disorders significantly increase cardiovascular and metabolic disease risks, partly due to antipsychotic-induced weight gain and glucose dysregulation.

Popular GLP-1 medications such as Ozempic may carry an unexpected link to a lower risk of epilepsy in people with type 2 ...

Semaglutide, a GLP-1 receptor agonist (RA), was associated with a significantly lower risk for adult-onset epilepsy in patients with diabetes than other glucose-lowering drugs (GLDs). Notably, this ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. What Happens If You Use Expired Semaglutide? Wondering what ...